Select Language

SLAMF7

SLAMF7 Overview

English Name	SLAM family member 7	Approved Drugs	1
Drugs in Clinical Trials	8	Target Synonym	CS1，UNQ576/PRO1138，SLAMF7，Novel Ly9，SLAM Family Member 7，Membrane Protein FOAP-12，CD2 Subset 1，Protein 19A，CRACC，CD2-Like Receptor Activating Cytotoxic Cells，CD2-Like Receptor-Activating Cytotoxic Cells，19A24 Protein，CD319，19A，CD319 Antigen，Novel LY9 (Lymphocyte Antigen 9) Like Protein
Highest Development Stage	Approved

English Name	SLAM family member 7
Target Synonym	CS1，UNQ576/PRO1138，SLAMF7，Novel Ly9，SLAM Family Member 7，Membrane Protein FOAP-12，CD2 Subset 1，Protein 19A，CRACC，CD2-Like Receptor Activating Cytotoxic Cells，CD2-Like Receptor-Activating Cytotoxic Cells，19A24 Protein，CD319，19A，CD319 Antigen，Novel LY9 (Lymphocyte Antigen 9) Like Protein
Approved Drugs	1
Drugs in Clinical Trials	8
Highest Development Stage	Approved

SLAMF7 Product List

Product Category
Protein (8)
Product Status
Launched (8)
Species
Human (6)Mouse (1)Rhesus macaque (1)
Tag
His Tag (5)Fc Tag (1)His Tag & Avi Tag (1)Mouse IgG Fc Tag (1)
Conjugate
Unconjugated (4)Biotin-labeled (1)FITC Labeled (1)PE Labeled (2)

Cat. No.	Species	Host	Product Description
HOT SL7-H5225	Human	HEK293	Human SLAMF7 / CRACC / CD319 Protein, His Tag, low Endotoxin (MALS verified)
HOT SL7-H82E0	Human	HEK293	Biotinylated Human SLAMF7 / CRACC / CD319 Protein, Avitag™,His Tag (MALS verified)
HOT SL7-HP2H3	Human	HEK293	PE-Labeled Human SLAMF7 / CRACC / CD319 Protein, His Tag (Site-specific conjugation)
HOT SL7-HP2H6	Human	HEK293	PE-Labeled Human SLAMF7 / CRACC / CD319 Protein, His TagStar Staining
HOT SL7-R52H7	Rhesus macaque	HEK293	Rhesus macaque SLAMF7 / CRACC / CD319 Protein, His Tag (MALS verified)
SL7-H5256	Human	HEK293	Human SLAMF7 / CRACC / CD319 Protein, Fc Tag
SL7-HF2H7	Human	HEK293	FITC-Labeled Human SLAMF7 / CRACC / CD319 Protein, His Tag
SL7-M5252	Mouse	HEK293	Mouse SLAMF7 / CRACC / CD319 Protein, Mouse IgG2a Fc Tag, low endotoxin

Total: 8

SLAMF7 Background

SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.

SLAMF7 Synonyms

SLAMF7,CD319,CS1,CRACC,19A,FOAP-12

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
SLAMF7 CAR-T cell therapy (Wuerzburg University Hospital)		Phase 2 Clinical	University Hospital Würzburg	Multiple Myeloma	Details
dual anti-CS-1/anti-BCMA CAR T-cell therapy (Wuhan Sian Medical Technology)		Phase 1 Clinical	Wuhan Sian Biotechnology Co Ltd	Multiple Myeloma	Details
BCMA-CS1 cCAR T-cell therapy		Phase 1 Clinical	iCell Gene Therapeutics LLC	Multiple Myeloma	Details
SA102-CAR-T	SA-102; SA102	Phase 1 Clinical	Wuhan Sian Biotechnology Co Ltd	Multiple Myeloma	Details
WS-CART-CS1	WS-CART-CS1	Phase 1 Clinical	Paula C. & Rodger O. Riney Blood Cancer Research, Washington University School Of Medicine	Multiple Myeloma	Details
MB-104	MB-104; MB-105; MB-104 CS1 CAR; MB-105 PSCA CAR	Phase 1 Clinical	City Of Hope National Medical Center	Glioblastoma; Multiple Myeloma; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms	Details
CS1 Targeted CAR T-cells (Yake Biotechnology)		Phase 1 Clinical	Shanghai YaKe Biotechnology Co Ltd	Multiple Myeloma	Details
CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology)		Clinical	Wuhan BioRaid Biotechnology Co Ltd	Hematologic Neoplasms	Details

Marketed Drug Information

English Name	Research Code	Highest Development Stage	Company	Earliest Brand Name	Earliest Approval Country	Earliest Indication	Earliest Approval Company	Earliest Approval Date	Indication	Clinical Trial
Elotuzumab	PDL-063; HuLuc-63; BMS-901608	Approved	Abbvie Inc, Bristol-Myers Squibb Company	Empliciti	United States	Multiple Myeloma	Bristol-Myers Squibb Company	2015-11-30	Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Leukemia, Plasma Cell; Lymphoma; Multiple Myeloma; Polycythemia Vera; Primary Myelofibrosis; Smoldering Multiple Myeloma; Thrombocythemia, Essential	Details